Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Endocyte's $2.1B Deal With Novartis Comes After Years Of Setbacks | 2018-10
LPNEWS

Endocyte's $2.1B Deal With Novartis Comes After Years Of Setbacks | 2018-10

by ibj.com posted 8months ago 39 views
The West Lafayette biotech firm's stock traded as low as $1.41 last fall, following multiple setbacks and restructurings. But the stock had soared to $24 Thursday morning after news that it would be acquired by Novartis.

In this article